Elsevier

Lung Cancer

Volume 64, Issue 3, June 2009, Pages 295-300
Lung Cancer

Epidermal growth factor receptor gene amplification in surgical resected Japanese lung cancer

https://doi.org/10.1016/j.lungcan.2008.10.005Get rights and content

Abstract

To evaluate the epidermal growth factor receptor (EGFR) protein expression and increased copy number as predictors of clinical outcome in patients with non-small-cell lung cancer (NSCLC), we have performed fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). We investigated the EGFR increased copy number and EGFR protein expression statuses in 109 surgically treated NSCLC cases. The presence or absence of EGFR mutations of kinase domains was analyzed by genotyping analysis and sequences, and already reported. EGFR increased copy number was defined as Cappuzzo et al. criteria. FISH positive was found from 36/109 (33.0%) lung cancer patients, including 30 high polysomy cases and 6 gene amplification cases. FISH-positive cases were significantly correlated with worse prognosis (log-rank test p = 0.0097). Within EGFR-mutant patients (n = 55), FISH-positive cases were also correlated with poor prognosis (p = 0.0255). FISH-negative tumors were found to be more frequently well-differentiated histology. Smoking status (never smoker vs. smoker, p = 0.1510), and gender (p = 0.5248) did not correlated with FISH positive. EGFR IHC results were correlated with FISH results (p = 0.004), but not correlated with prognosis (p = 0.2815). Although EGFR FISH-positive rate did not correlated with EGFR mutation (p = 0.1973), EGFR polysomy or amplification cases were correlated with EGFR mutations (p = 0.0023). In conclusion, the EGFR FISH-positive rate in Japanese patients with NSCLC was similar to rates in Western populations, unlike the higher frequencies of EGFR mutation in East Asians. A high EGFR gene copy number might have shorter survival in NSCLC.

Introduction

Despite improved surgical techniques and systemic chemotherapy treatments, patients with non-small cell lung carcinoma (NSCLC) have about 15% 5-year survival after initial diagnosis. The epidermal growth factor receptor (EGFR) that was discovered almost three decades ago has emerged as a leading target for the treatment of patients with NSCLC [1]. Inhibition of the EGFR pathway by a monoclonal antibody against the receptor or a small molecular inhibitor of the receptor tyrosine kinase is being evaluated as therapy for various malignant neoplasms. Recently, it has been shown that specific mutations in the EGFR gene may identify lung cancer patients with a good response to the tyrosine kinase inhibitor [2], [3], [4], [5], [6]. On the other hand, Cappuzzo et al. reported that EGFR amplification by fluorescence in situ hybridization (FISH) and high EGFR protein expression has been associated with responsiveness to gefitinib [7]. Takano et al. showed that EGFR gene mutation and increased copy numbers both predicted gefitinib sensitivity in patients with recurrent NSCLC [8], although this Japanese report based on polymerase chain reaction (PCR) assay. Recently, several reports have shown that EGFR FISH assay predicted for response to anti-EGFR antibody treatment in colon cancer [9], [10]. On the other hand, the trend for shorter survival in EGFR FISH positive in NSCLC was reported [11], [12].

The prognostic association of EGFR overexpression in lung cancer is a controversial issue. Different conclusions regarding prognostic significance may reflect differences in detection methods, reagents, assay cutoff points, and population characteristics. The EGFR gene, located on chromosome 7p12, has been found amplified in low frequency by Southern blot [13] and polymerase chain reaction analyses [14], [15]. To determine the EGFR increased copy number and correlation with clinico-pathological features in Japanese NSCLC, we retrospectively performed FISH and immunohistochemistry, according to the Cappuzzo criteria [7]. The findings were compared to the clinico-pathologic features of lung cancer.

Section snippets

Patients

This was a retrospective study and the study group included 109 lung cancer patients who had undergone surgery at the Department of Surgery II, Nagoya City University Medical School. Written informed consent was obtained and the institutional ethics committee of the Nagoya City University Medical School approved the study. The lung tumors were classified according to the general rule for clinical and pathological record of lung cancer in Japan. All tumor samples were immediately frozen and

EGFR gene copy number by FISH

First we assessed EGFR copy number by FISH according to the Cappuzzo et al. criteria [7]. High polysomy for the EGFR gene was present 27.5% (n = 30), and gene amplification in 5.5% (n = 6) (Fig. 1). For FISH-positive tumors, the proportions of well, moderately, and poorly differentiated histopathology were 45.7% (16/35), 40% (14/35), and 14.3% (5/35), respectively. One case was adenosquamous carcinoma. And for FISH-negative tumors, the corresponding proportions were 65.7% (46/70), 20.0% (14/70),

Discussion

We obtained findings that EGFR increased copy number, detected by FISH according to the Cappuzzo et al. criteria, was associated with shorter survival of NSCLC, even within the EGFR-mutant cases. This was in agreement with the recent reports that EGFR gene amplification was prognostic factor for NSCLC [5], [12]. Another report suggested that NSCLC patients with resected tumors carrying high EGFR gene copy number have a tendency to a shorter survival [20]. In a phase III placebo-controlled study

Conflict of interest

None declared.

Acknowledgements

We thank Nihon Gene Research Laboratories Inc. (Drs. Narusawa and Shimada) for suggesting that they use fluorescence in situ hybridization to test for epidermal growth factor receptor gene amplification.

References (26)

  • H. Sasaki et al.

    Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer

    J Cancer Res Clin Oncol

    (2008)
  • F. Cappuzzo et al.

    Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

    J Natl Cancer Inst

    (2005)
  • T. Takano et al.

    Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

    J Clin Oncol

    (2005)
  • Cited by (0)

    Grant Sponsor: AstraZeneca Research Grant 2004, Grand-in-Aid for Research in Nagoya City University (2006), and Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science (JSPS) (Nos. 19390367, 18390381, 18659407).

    View full text